|
|
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- NHS Trusts (England) - Medical Director
- NHS Trusts (England) - Chief Executive
- Out of hours contacts
|
|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- Special Health Authorities
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
|
| Title: |
|
Interleukin-6 inhibitors (tocilizumab or sarilumab) for hospitalised patients with COVID-19 pneumonia (adults)
|
| Broadcast content: |
|
NHS
trusts / health boards are recommended to consider prescribing a single dose of
tocilizumab to eligible hospitalised patients with COVID-19 pneumonia,
typically as adjuvant treatment to dexamethasone as standard of care, following
the announcement of the findings of the RECOVERY trial. Sarilumab continues to be recommended for
critically ill patients being treated with non-invasive
ventilation or invasive mechanical ventilation, who have not already
received tocilizumab.
|
| Additional information: |
|
This alert is not relevant to Primary Care.
|